Phase I, Phase I-II
A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Study Locations
- Smilow Cancer Hospital Care Center - Trumbull (CT053)
- Yale University
Principal Investigator
Sub-Investigators
- Last Updated10/13/2026
- Study IRB#2000042905